Loading…

Septerna, Inc.SEPNCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.

Momentum leader 81
Mkt cap
$1.88B
US dollars, full cap
Free float
64%
of shares outstanding
$/day
$19.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 15.9%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$39.45
1D-1.4%
1W-18.8%
1M+0.2%
3M-3.3%
6M+40.8%
YTD+41.5%
1Y+82.3%
ATR %8.1%
Beta0.99
52w lowhigh26.0% off high

What Septerna does

Develops oral small-molecule drugs targeting G protein-coupled receptors using a proprietary structural platform.

Has no approved drug; income is upfront and milestone payments from pharma partners such as Otsuka, plus money raised from investors. Its platform keeps receptor proteins in their working shape outside living cells so they can be studied and screened, and partners pay to use it on their chosen targets.

Products and services

  • Endocrine/metabolic GPCR pipeline
  • Partnered pipeline (Otsuka collaboration)

Customers

  • Endocrinologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • GPCR-targeted drug discovery

What could go right

  • Platform-driven pipeline expansion
  • Partnership milestone payments

What could go wrong

  • Early-stage/preclinical pipeline risk
  • Competitive GPCR drug discovery field

Moat: narrow (IP / patents, process know-how). Proprietary native GPCR structural platform enables drugging previously undruggable receptor targets.

Headquarters: South San Francisco, California, US · Founded: 2019 · Employees: 130

Named competitors

Septerna at a glance

Size Septerna (SEPN) is a United States Health Care company (Biotechnology) with a market value of $1.88B, the 1810th largest of 3,085 United States companies the cockpit tracks. Shares closed at $39.45 on 18 Nov 2026.

Performance Over six months the shares gained 40.8%, against -4.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue grew 336.7% over the last twelve months (peer median +5.5%); the operating margin is -76.2% (peer median -29.7%).

Valuation It trades at 14.7× enterprise value to sales against a peer median of 12.6× (7th most expensive of 15).

Short interest Short interest is 7.2% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026SEPN 141Peer median 93
Six months, rebased to 100: Septerna against the median of its 20 peers (local-currency closes).

Septerna financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$96.3M$46.0M$1.07M$151,000$0
Revenue growth—+4,175%+612%——
Gross profit$94.6M$44.3M-$326,000-$697,000-$577,000
EBITDA-$71.7M-$79.2M-$79.4M-$44.7M-$27.4M
Net income-$59.0M-$48.9M-$71.8M$567,000-$27.7M
Free cash flow-$77.6M$110M-$69.6M-$41.6M-$24.6M
Capital expenditure$1.02M$518,000$2.10M$2.88M$1.29M
Total debt$22.0M$23.6M$25.5M$12.6M$710,000

Quarterly statements and history in the cockpit →

Septerna competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%REPLBCRXTRAX300601VERAMRVICOAGTRVIZBIO688046RXRXSTOKALMRSEPN6-month return →1-month return →
Up and to the right = strong over both horizons. Septerna is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%+200%+300%0×50×100×150×BCRX300601688520MRVIZBIO688046RXRXSTOK145020ALMRSEPNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Septerna is the large dot.

Septerna competitors and peer comparison

Head to head with its named competitors (SEPN vs GPCR vs ASMB vs CRNX)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Septerna SEPN$1.88B+41%+337%-76%14.7×n/a
Structure Therapeutics, Inc. Sponsored ADR GPCR$1.24B-53%n/an/an/an/a
Assembly Biosciences ASMB$458M-15%+80%-32%2.2×n/a
Crinetics Pharmaceuticals CRNXn/a+109%n/an/an/an/a
Viking Therapeutics VKTX$3.34B-9%n/an/an/an/a

How Septerna compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Septerna against its 20 peers (data as of 18 Nov 2026)
MeasureSEPNPeer medianRank in peer set
1-month return+0.2%-6.2%9th highest of 20
6-month return+40.8%-4.7%6th highest of 19
Distance from 52-week high-26.0%-34.3%7th highest of 21
Revenue growth (TTM)+336.7%+5.5%highest of 15
Operating margin-76.2%-29.7%6th lowest of 15
EV / Sales14.7×12.6×7th most expensive of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Septerna SEPNUnited States$1.88B+41%+337%-76%14.7×n/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%2.4×-11.0%+117.9%
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%4.9×22.7%+3.4%
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%149.9×n/an/a
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%13.6×n/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%10.2×n/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%146.1×n/an/a
GemPharmatech 688046.SSChina$1.78B+39%+25%22%11.7×33.0%+24.8%
Immunome IMNMUnited States$1.98B-22%-100%n/an/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%18.8×n/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%50.6×n/an/a
Aurinia Pharmaceuticals AUPHUnited States$2.03B-5%+21%45%5.0×3.5%+41.4%
Evopoint Biosciences 688837.SSChina$2.08Bn/an/an/a53.6×n/an/a
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%3.6×-12.1%+15.0%
Alamar Biosciences ALMRUnited States$2.12B+51%+195%-42%26.1×n/an/a
BGI Genomics 300676.SZChina$2.13B-15%0%-14%3.2×n/an/a

Questions

Who are Septerna's main competitors?
Named competitors: Structure Therapeutics (GPCR), Sosei Heptares (private or unlisted), Assembly Biosciences (ASMB), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX). The cockpit's measured peer set (industry) also includes Replimune (REPL), BioCryst Pharmaceuticals (BCRX), First Tracks Biotherapeutics (TRAX), Shenzhen Kangtai Biological Products (300601.SZ), Vera Therapeutics (VERA), Sinocelltech (688520.SS).
Is Septerna expensive compared with its peers?
On ev / sales it trades at 14.7× against a peer median of 12.6×, 7th most expensive of 15 in its peer set.
How has Septerna stock performed?
Over six months to 18 Nov 2026 the shares returned +40.8% against -4.7% for the median peer; over one year +82.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.